Ardelyx shares data from studies of XPHOZAH at ASN Kidney Week 2023

Ardelyx shared positive data on the use of XPHOZAH in poster presentations at the American Society of Nephrology, ASN, Kidney Week 2023 meeting, currently being held in Philadelphia, Pennsylvania, and will showcase XPHOZAH in an Exhibitor Spotlight event. Ardelyx’s presence at Kidney Week 2023 will honor the memory of Derek Forfang, Chair of the Ardelyx Patient Advisory Council and a passionate advocate for patients with kidney disease. The first poster, titled Optimal Initiation of Tenapanor Treatment Analyzed by Baseline Phosphate Binder Dose: A Sub-analysis of the OPTIMIZE Study, looked at serum phosphate control across two cohorts of patients by phosphate lowering pill burden. The OPTIMIZE study showed that both cohorts experienced improved sP control and improved patient reported quality of life, as well as a reduction in pill burden. In a poster titled Patient Education Improves Adherence to Tenapanor Treatment in OPTIMIZE Study, researchers looked at the effect of patient education on adherence, using data from the OPTIMIZE study compared to data from two phase 3 clinical studies of tenapanor, BLOCK and PHREEDOM. The study found that this educational information improved adherence, and may have specifically reduced medication discontinuation due to changes in bowel habits. The third poster, Safety Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in Patients on Maintenance Dialysis with Hyperphosphatemia, reviewed patient data from the PHREEDOM study that evaluated tenapanor for the treatment of hyperphosphatemia in patients with CKD on maintenance dialysis. The study showed that a lower proportion of patients treated with tenapanor versus sevelamer experienced a serious adverse event while the exposure adjusted rates were similar. This analysis also showed that the incidence of adverse events leading to hospitalization was lower in the tenapanor arm than the sevelamer arm while the exposure adjusted rates were similar. The final Ardelyx poster to be shared at ASN, Tenapanor in Combination with Phosphate Binders Improves Short and Long-Term Control of Serum Phosphate in Patients on Dialysis with Hyperphosphatemia.